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1. Introduction 20 
 In vitro dissolution studies are an integral part of quality control and drug development 21 
processes. During drug development, they are used as a tool for the selection of the appropriate 22 
excipients and the most suitable formulation type [1] and also as an in vitro surrogate for in 23 
vivo performance [2]. In quality control, they are used to ensure the batch-to-batch consistency. 24 
[3-5]. Dissolution tests, as dictated by the Pharmacopoeias though, cannot always provide 25 
information about the in vivo behaviour of the drugs, even though there are cases in which these 26 
tests can provide good in vitro–in vivo correlations (IVIVC). The dissolution media described 27 
in Pharmacopoeia monographs are mainly used for quality control purposes, and are not often 28 
able to predict the in vivo behaviour of poorly soluble drugs for which the fat content and the 29 
bile salts concentration in the gastrointestinal environment will affect their solubility and 30 
dissolution rate [6, 7]. Due to the limited ability of the simple aqueous media suggested by the 31 
Pharmacopoeias to simulate the characteristics of the gastrointestinal (GI) tract, the need for 32 
media simulating the GI physiological environment in the fasted and fed states (usually called 33 
biorelevant media) arose; in these media the physicochemical properties of the GI contents 34 
(pH, osmolality, surface tension, buffer capacity) are taken into account and physiological 35 
components such as bile salts and lecithin are incorporated [2]. Use of biorelevant media during 36 
the drug development process enables the assessment of drug’s biopharmaceutic characteristics 37 
and the prediction of in vivo performance [2, 8]. 38 
While the fasted state gastric environment has been well studied, the more complex 39 
conditions of the fed state stomach have made the prediction of food effect a challenging task. 40 
Several in vitro biorelevant gastric media have been used for the simulation of the gastric fed 41 
state environment and as far as the sample treatment is concerned, there is no specific protocol 42 
available and sample treatment and drug analysis are developed on a case by case basis. A good 43 
understanding of the in vivo conditions of the fed state stomach could lead towards the 44 
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development of a suitable medium being able to simulate the gastric content and ideally 45 
overcoming the extensive treatment before the analysis that is needed with the current gastric 46 
fed state media [9, 10]. The dependence of the drug food effect on the meal content, the role of 47 
the fat content in the solubilisation of drugs, the gastric emptying rate and the interaction with 48 
certain formulations [11] as well as the binding of drugs with metal ions and meal components 49 
are some of the parameters which have rendered the in vitro prediction of food effect extremely 50 
complicated. 51 
In the current review, initially we describe the available information for the 52 
characterisation of the in vivo gastric fed state conditions after the administration of standard 53 
meals with an aim to provide an understanding of the effect of drug’s physicochemical 54 
parameters on its in vivo behavior. Then, the standard meals and the gastric biorelevant media 55 
currently being used and their interaction with drugs of different physicochemical properties 56 
are presented. In the last part the analytical techniques used in vitro for sample treatment and 57 
quantification of the drug along with their challenges are discussed. 58 
 59 
2. In vivo gastric conditions in the fed state 60 
 61 
 Gastric conditions in fasted state have been characterised in terms of pH, osmolality, 62 
surface tension, buffer capacity and protein content [12-14]. In the fed state though, the 63 
determination of absolute values is more complicated than in the fasted state. The food type is 64 
an additional factor on top of other parameters responsible for the interindividual variation of 65 
the above properties such as the individual’s age [15] and administered medication [16]. The 66 
role of several physicochemical parameters of the contents of the fed state stomach on drug’s 67 
dissolution and absorption is reviewed. 68 
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 69 
2.1. Gastric secretions in the fed state 70 
 The main components of the gastric juice are hydrochloric acid (HCl), pepsinogens, 71 
mucus and water; pepsinogen is the inactive form of pepsin, activated by the presence of HCl 72 
[17]. Pepsin content is higher in the fed state stomach than in the fasted state (fasted state values 73 
= 0.11–0.22 mg/mL). Samples of gastric antrum content of twenty healthy volunteers after 74 
administration of Ensure Plus®, demonstrated pepsin values within a range from 0.26 to 0.58 75 
mg/mL in a time period from 30 to 210 minutes after administration of the liquid meal [13]. 76 
Gastric lipase is also present in the stomach. It is the enzyme responsible for the digestion of 77 
fat in the upper gastrointestinal tract. Its role involves the hydrolysis of exogenously 78 
administered triglycerides to di-glycerides and fatty acids [18]. Gastric lipase is has been 79 
reported to account from 10-30% of the total hydrolysis of triglycerides contained in a meal 80 
[19, 20] with the activity of the enzyme measured  at 11.4–43.9 U/mL [21]. Its total output 81 
after administration of a liquid meal was 22.6 ± 8.1 mg (concentration 16.7 ± 0.7 μg/mL) after 82 
administration of a liquid meal in human subjects [19]. 83 
2.2. Bile salts in gastric contents in the fed state 84 
 Bile salts can increase the dissolution of poorly soluble drugs by decreasing the energy 85 
barrier between the drug and the medium, by increasing the active surface area, or via micellar 86 
solubilisation [22]. Bile salt concentration in the stomach is much smaller than in the small 87 
intestine, where the bile salts are released by the gall bladder, with their concentration in the 88 
intestinal environment in the fasted state demonstrating an approximate 4-fold decreased value 89 
in comparison to the fed state (1-4 mM and 10-20 mM, respectively) [23, 24]. In the gastric 90 
fed state (after administration of 500 mL Ensure Plus®) only traces of bile salts have been 91 
reported (60 μΜ) [13]. Similar bile salts concentration (51 μM) were measured in the fed state 92 
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stomach of healthy subjects after a standard lunch (13.5 g protein, 18 g corn oil, and 53 g 93 
carbohydrate in 300 mL water) [25].  94 
2.3. Proteins, lipids and carbohydrates in gastric contents in the fed state 95 
The protein, lipid and carbohydrate content in the fed state stomach is dependent on the 96 
type of meal consumed before the administration of the drug, therefore their concentration is 97 
highly variable and cannot be expressed solely by the results of a single study. Indicatively, the 98 
concentrations of proteins and carbohydrates after administration of 500 mL Ensure Plus® to 99 
healthy subjects were found to be 23.3 mg/mL and 152.1 mg/mL at 30 min respectively, 100 
decreasing to 11.2 mg/mL and 49.1 mg/mL at 210 min after the liquid meal’s administration 101 
[13]. 102 
 103 
2.4. pH of gastric contents in the fed state 104 
The pH affects dissolution and absorption of both actively and passively absorbed 105 
drugs. The non-ionised fraction of the drug is more efficiently absorbed during passive 106 
absorption, while the affinity of the drug carrier for the ionised or non-ionised fraction defines 107 
the rate of active absorption [26, 27]. The pH of the stomach in the fed state is significantly 108 
higher than in fasted state (pH ≈ 1.7) [13, 28] with a wide range of values between 3-7 [1]. The 109 
pH increases up to approximately a value of 6.5 after a meal and decreases exponentially 110 
reaching a value of 2-2.7, similar to the pH value measured in the fasted state after 3-4 hours. 111 
In case of patients suffering from hypochorhydria/achlorhydria due to pathological conditions 112 
(i.e. AIDS; Acquired Immune Deficiency Syndrome) or administered medication (H2 receptor 113 
antagonists or Proton-Pump Inhibitors), initial fasted pH values are elevated compared to the 114 
values mentioned above, reducing the dissolution rate of basic drugs [29, 30]. Thirty minutes 115 
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after administration of 500 mL of a nutrient drink (Ensure Plus®), Kalantzi et al. reported a pH 116 
value of 6.4 in the gastric aspirates of twenty human subjects (Figure 1) and a decrease of the 117 
gastric pH to a value close to the fasted state three and a half hours after the liquid meal’s 118 
administration [13]. The gradual decrease in gastric pH values is attributed to the induction of 119 
secretion of gastric acid after the administration of a meal and to the meal’s buffering properties 120 
[22]. Another in vivo study [21] showed that after administration of a liquid standard meal 121 
containing 65% fat, 29.5% carbohydrate and 5% protein, the pH reaches a maximum of 4. A 122 
study by Yamaguchi et al. [31], which monitored the gastric pH of human subjects using a 123 
Bravo® pH monitoring system, with the aid of a capsule placed on the gastric wall, confirmed 124 
also the immediate burst and gradual decrease to the fasted state level pH, with it returning to 125 
its initial value 2 hours after the administration of a meal. The subjects of the above study were 126 
monitored for 48 hours and did not follow any restriction in their dietary routine. The absolute 127 
values of these two studies cannot be compared though, as the subjects of the latter did not 128 
follow a specific diet. The time needed for the gastric pH levels to return to the initial values 129 
and the pH “peak” value of the fed state are dependent upon the type of standard meal 130 
administered during each in vivo study, the age of the subject and the experimental protocol 131 
followed [32]. For instance, the pH decreases to the fasted state value is faster after the 132 
administration of a liquid meal than after a solid meal. Gastric pH mostly affects the dissolution 133 
of drugs with a pKa value close to the physiological pH values, as when ionised behave as 134 
week electrolytes with their solubility being increased in comparison to their un-ionised form 135 
[27]. Therefore, changes in gastric pH mostly affect weak acids and weak bases with the 136 
increased values in the fed state enhancing the dissolution of acids and reducing the dissolution 137 
of bases. Gastric pH can also affect drug release. Coatings with pH-dependent disintegration 138 
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properties, like enteric coatings which dissolve rapidly in pH values of 4.5-8 [21] may 139 
experience different disintegration profiles due to elevated fed pH value.  140 
 141 
2.5. Osmolality of gastric contents in the fed state 142 
Osmolality can affect drug’s dissolution rate by inducing changes in the swelling 143 
behavior of the formulation. Osmolality is linked with water penetration in the formulation; 144 
when the difference in osmotic pressure between the inner and outer (GI environment) part of 145 
the formulation decreases, water penetration decreases as well, affecting negatively drug 146 
release [33]. The gastric fluids in the fed state are slightly hyperosmotic 30 minutes after 147 
administration of Ensure Plus® (559 mOsm kg-1), and their osmolality is decreased to 217 148 
mOsm kg-1 3.5 h after the administration [13], revealing that the osmolality of the gastric 149 
contents returns to the fasted state value during this time period (191± 36 mOsm kg-1 based on 150 
measurements of 24 healthy subjects) [12]. 151 
 152 
2.6. Surface tension of gastric contents in the fed state 153 
 The surface tension of the fed gastric fluids is lower than the one of an aqueous solution 154 
due to the presence of surface tension lowering compounds, such as bile salts entering the 155 
stomach through duodenal reflux and acting as surfactants, pepsin and food components [34]. 156 
Pepsin is an enzyme produced in the mucosal lining of the stomach and acts as a digestive 157 
protein in the gastric environment. Since the lowest surface tension values acquired after the 158 
addition of biorelevant concentrations (0.003-0.195 mg/mL) of the enzyme (fasted state) in an 159 
acidic solution (pH 1.6, HCl solution with 2 g/L NaCl) were 57 mN/m, it can be assumed that 160 
other surfactants are present as well in both fasted and fed state gastric fluids, as their surface 161 
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tension value was significantly lower with a value of about 30-31 mN/m in the fed state and 162 
33-43 mN/m in the fasted state [4, 35, 36].  163 
 164 
2.7. Buffer capacity of gastric contents in the fed state 165 
 The buffer capacity of the medium can have a great effect on drug’s dissolution in 166 
combination with its pH, as change in pH can affect the ionisation percentage and consequently 167 
the solubility of ionisable drugs and excipients. In the fasted state, bicarbonate is the buffer 168 
mainly present in the stomach [37]. In the fed state though, the buffer capacity is dependent 169 
mainly on the meal contents than on the stomach’s mucosa, making this chemical property 170 
highly meal-dependent [37]. Buffer capacity at gastric fed state conditions after administration 171 
of Ensure Plus® is around 14-28 mmol/L·DpH based on in vivo measurements [13]. 172 
 Table 1 summarises the physicochemical properties of the contents of the gastric fed 173 
state environment, as measured in vivo in human subjects. 174 
 175 
3. Drug properties that relate to potential food effect  176 
Food effects can be induced via the direct interaction of drugs, due to their unique 177 
physicochemical properties, with food components [38]. Such interactions include formation 178 
of insoluble complexes (i.e. tetracyclines and calcium ions) [39], binding to proteins (i.e. 179 
phenytoin) [40], or interaction/exchange of drugs with anionic or cationic sites of dietary fibers 180 
(i.e. metformin) [41]. In this section the drug properties that can affect drug dissolution and 181 
absorption leading to a potential food effect are described.  182 
 183 
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3.1. Ionisation (pKa) 184 
 185 
The pKa determines the percentage of a drug’s charged/uncharged form under certain 186 
pH conditions and affects the solubility of drugs at differing media pH. Solubility and 187 
dissolution of weekly acidic drugs is low at the pH of the fasted stomach as they are mostly in 188 
their unionised form. At fed state conditions, where the pH is higher, their gastric solubility 189 
and dissolution increase with a subsequent effect on their pharmacokinetics [6]. The uncharged 190 
state of the drug has a positive effect on membrane permeability, as the fraction of the unionised 191 
form of a drug is proportional to its lipophilicity [42]. As far as weekly basic drugs are 192 
concerned, their gastric solubility and dissolution is lower due to the higher pH of the stomach 193 
in the fed state in comparison to the fasted state. For compounds which are non-ionisable in 194 
the gastric environment a gastric fed state dissolution test is essential [6], as the type of meal 195 
consumed affects the surface tension of the gastric contents and thus, the active surface area 196 
which is available for drug solubility and dissolution [43]. 197 
3.2. Lipophilicity (log P, log D) 198 
 199 
Partition coefficient, log P, is indicative of the lipophilicity of a compound and 200 
determines the partition of a compound in a system of n-octanol/water. For an ionisable 201 
molecule the apparent partition coefficient (log D) is the value which expresses the partition in 202 
the aqueous and organic phase in a more accurate way as it takes into consideration its 203 
ionised/unionised percentage and therefore log D values vary according to the pH of the 204 
environment. Log P values are related to drug’s affinity for biological membranes and target 205 
sites affecting its biological activity [42]. Ideally, the drug should have such a hydrophilic- 206 
lipophilic balance so that it can be dissolved in the biological fluids, where the site of absorption 207 
is, and also be able to permeate the membranes of the site of action. Drug’s lipophilicity is 208 
believed to have an important role in its dissolution in the gastric fed state, as solubility and 209 
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dissolution of lipophilic drugs in the fed stomach is performed through their partitioning in the 210 
lipid fraction of the meal during its breaking into particles throughout digestion before reaching 211 
the small intestine [6].  212 
 213 
3.3. Solubility 214 
 215 
Solubility is a key drug property for its potential oral absorption. Due to the prolonged 216 
residence of the drug in the gastric environment during the fed state, the solubility in the gastric 217 
contents will affect drug’s dissolution and subsequent absorption. The wetting and 218 
solubilisation of drugs co-administered with food can be increased by the digestion products 219 
of lipolysis products in the gastrointestinal tract (Figure 2) [22]. The gastric compartment is 220 
the part of the gastrointestinal tract where the dietary lipids are emulsified at first place. 221 
Facilitated by gastric lipase, gastric agitation and emptying, protein and polysaccharide 222 
contents along with lypolytic triglyceride products stabilize the interface between lipid and 223 
aqueous phase [18]. Therefore, the presence of gastric lipase in the fed stomach is important 224 
when biorelevance need to be achieved for in vitro assays. Aqueous media usually give an 225 
underestimation of the drugs’ solubility in the gastric environment. An underestimation of 226 
solubility was also observed for undigested milk, suggesting that apart from having the same 227 
pH, buffer capacity, protein content and osmolality, the presence of enzymes should be 228 
considered for a good prediction of drug’s solubility in the gastric environment [44]. If not 229 
adequately soluble in the gastrointestinal fluids, drugs orally administered can have a solubility 230 
limited dissolution and non-linear dose responses due to inadequate drug in solution in the site 231 
of absorption [42].  232 
 233 
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3.4. Biopharmaceutics Classification system (BCS) and Food effect 234 
 235 
Amidon and co-workers [45] defined drug aqueous solubility and permeability as 236 
determining parameters which control a drug’s systemic in vivo absorption and introduced the 237 
Biopharmaceutics Classification System (BCS) which categorizes the drugs in four classes 238 
according to their aqueous solubility and permeability: 239 
BCS I compounds: high solubility-high permeability 240 
BCS II compounds: low solubility-high permeability 241 
BCS III compounds: high solubility-low permeability 242 
BCS IV compounds: low solubility-low permeability 243 
Fleischer et al. [46] proposed a food effect predictive model for the drugs’ absorption 244 
according to their drugs’ BCS class (delayed/no effect for BCS class I, increased with fat 245 
content for BCS class II, decreased for BCS class III, low and non-predictable for fed/fasted 246 
states for BCS class IV); this model is only a general guideline as many drugs do not follow 247 
this pattern. The reason is that except for BCS class I drugs, the drugs belonging to the other 248 
BCS classes have a wide range of properties and consequently different rate limiting steps for 249 
drug absorption. For example, a low solubility compound with absorption just under 90% is 250 
classified as a class IV compound, but it is unlikely that its permeability would be the rate 251 
limiting step for its absorption [47]. Based on the BCS classification, Wu and Bennet [48], 252 
correlated the interactions of the different BCS class drugs with intestinal efflux and reflux 253 
transporters. It was suggested that for BCS class II compounds, the relative magnitude of the 254 
inhibition between efflux and influx transporters with additional solubilisation in the intestinal 255 
environment and gastric emptying are the two parameters affecting the drugs’ absorption, with 256 
the latter process being the detrimental one. Inhibition of influx transporters was suggested for 257 
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the negative food effect for most BCS class III compounds, while BCS class IV compounds 258 
combine all the above mechanisms for BCS class II and III drugs (Table 2) making the 259 
prediction of food effect difficult [49].  260 
 261 
4.  Standard meals used in BA/BE studies 262 
 263 
 Homogenised standard meals have been used as an attempt to simulate gastric fed state 264 
conditions. In order to determine the effect of food on drug absorption, both the Food and Drug 265 
Administration (FDA) and the European Medicine Agency (EMA) recommend the use of a 266 
high-fat meal for the determination of drug’s pharmacokinetic parameters in the fed state as 267 
the worst case scenario [50]. Meals which are of a high caloric and fat content are 268 
recommended in BA/BE studies as these are more likely to affect gastric physiology and have 269 
a more pronounced effect on drugs [51]. As a high-fat and high-calorie meal FDA suggests a 270 
meal of 800-1000 caloric content with ~50% of the calories deriving from its fat content with 271 
150, 250 and 500-600 kilocalories (kcal) being obtained by protein, carbohydrate and fat, 272 
respectively [51]. An example of a typical high fat standard breakfast as proposed by the FDA 273 
used in a bioequivalence study for Cicloral® and Neoral®, (100 mg cyclosporine A 274 
formulations) [52] is: “2 eggs fried in butter, 2 strips of fat bacon, 120 g hash brown potatoes, 275 
250 mL whole milk, and 1 croissant”. For food effect studies, EMA suggests a similar 276 
standardised high fat meal (800-1000 kcal caloric content, 500-600 and 250 of which derive 277 
from fat and carbohydrates, respectively) and a moderate meal of ~400-500 kcal with ~150 278 
kcal deriving from fat [50]. As far as the dosage strength to be tested in fed state studies is 279 
concerned, FDA recommends the testing of the highest dose to be marketed and lower doses if 280 
the testing of the former is not possible for safety reasons [51]. According to EMA, the highest 281 
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and lowest doses in the drug therapeutic range have to be tested when the drug follows 282 
nonlinear pharmacokinetics [50]. 283 
Apart from the meals described previously, other types of meals can also be used in the 284 
investigation of the effect of food in drug’s pharmacokinetics in cases of a specific food effect 285 
mechanism. For example, a high-protein meal (80 g protein, 52 g carbohydrate, 9 g fat) was 286 
used in the investigation of the pharmacokinetics of gabapentin, an anticonvulsant, whose 287 
transport through the biological membranes is controlled by System-L, the L-amino acid 288 
transport system [53]. Klein et al. [43] characterised two standard meals (GSK high fat-(62%) 289 
standard meal and FDA intermediate fat (37%) standard meal), constituted by homogenised 290 
eggs, bacon, butter, milk and other ingredients indicative of a median diet (Table 3). The 291 
purpose of the study was the comparison of their physicochemical properties with those of the 292 
meals, such as milk and nutrient drinks currently being used for the simulation of fed-state 293 
conditions in dissolution studies.  294 
 295 
5. In vitro simulation of gastric conditions in the fed state (Biorelevant dissolution 296 
media) 297 
 298 
Even though actual homogenised meals are able to simulate gastric state conditions the 299 
best, problems in the analysis of the drugs led to the development of alternative approaches 300 
[37, 54]. A range of dissolution media have been developed in order to simulate the in vivo 301 
conditions of the fed state stomach (Table 4). These media were developed with the aim of 302 
having the same physicochemical properties with the standard meal recommended by FDA for 303 
BA/BE studies [51].  304 
5.1. Milk-based media 305 
 306 
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 Milk 307 
Milk started being used as a dissolution medium for gastric fed state simulation about 308 
twenty years ago. Machairas et al. successfully used low fat milk (0.75% fat) with a flow 309 
injection serial dynamic dialysis technique (FISDD) as a food simulation medium for drug 310 
dissolution, for four drugs of different physicochemical properties; salicylamide, 311 
acetaminophen, propantheline and nitrofurantoin. Milk was selected as a dissolution medium 312 
in this study due to its potential as substrate of the gastric fed conditions and also due to its use 313 
as a vehicle in drug delivery systems [55]. Furthermore, its energy content is similar to that of 314 
a standard meal administered to the subjects participating in bioavailability/bioequivalence 315 
studies [56]. Despite its similarities with the gastric environment in the fed state, the use of 316 
milk does not always simulate the gastric fed state ideally. The issues of the use of milk as a 317 
dissolution medium relate to its lower values in osmolality (285 ± 2.7 mOsmol kg-1) and buffer 318 
capacity (13.9 ± 0.2  mEq pH-1 L-1) at 37 °C compared to the standard high-fat breakfast 319 
proposed by the FDA (771 ± 10 mOsmol kg-1 and 30.1 ± 1.8 pH-1 L-1, respectively) [43]. Other 320 
issues relate to its higher pH value (pH ≈ 6.5) than the equivalent pH of gastric media after a 321 
meal (5.8 ± 0.2 after 50% of gastric emptying after liquid meal administration) [56], and the 322 
possible need of supplementary enzyme addition due to the digestion of milk’s lipids and 323 
proteins taking place in vivo [6].  324 
In 1998, Galia et al. [58], assessed the suitability of full fat milk as a biorelevant gastric 325 
fed state medium for the evaluation of the dissolution behavior of one BCS class I drug 326 
(acetaminophen) and two BCS class II drugs (danazol, mefenamic acid). The results of this 327 
study demonstrated that for BCS class I drugs there is a strong dependence between the 328 
absorption and the type of formulation, with the interaction between the fed matrix and 329 
excipients controlling the absorption rate. Milk’s high content in lipids enhances the solubility 330 
and dissolution of lipophilic drugs; for instance, release of danazol, a BCS class II drug, in 331 
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milk, was substantially higher than in water. Furthermore the pH of milk (pH ≈ 6.5) favours 332 
the dissolution of weak acids, such as mefenamic acid [58]. Diakidou and co-workers showed 333 
that despite milk’s similarity in pH and protein contents with human aspirates after 334 
administration of a liquid meal, the solubility values of two BCS class II weak bases 335 
[dipyridamole (pKa 5.7–6.4, log P 2.7) and ketoconazole (pKas 2.9, 6.5; log P 4.4)], were 4.7 336 
and 3.6 times lower in milk (after the addition of pepsin and lipase from Rhizopus niveus) than 337 
in the gastric fed-state aspirates, respectively [44].  338 
 339 
 Digested milk 340 
After administration of a meal in vivo, digestion takes place. In vitro digestion milk 341 
models have been used for simulation of the in vivo digestion of gastric contents. These in vitro 342 
milk based models, take into consideration the role, amount and activity of the physiologically 343 
existing gastric enzymes in the fed state.  344 
In a milk based medium, HCl, lipase and pepsin have been added [44, 59, 60]. Two 345 
models using bovine milk were considered for the simulation of gastric environment. In the 346 
first model the dissolution of L-sulpiride, a hydrophilic weak base was studied in milk digested 347 
with pepsin and HCl [60], with 4.4 mg of pepsin from hog stomach dissolved in HCl being 348 
added every 15 min for a 90 min time period. The dissolution assay was performed in USP 349 
Apparatus 2 (100 rpm, 500 mL volume). The second model used milk digested with 350 
pepsin/HCl/lipase from Rhizopus niveus aiming to simulate the fed gastric environment after 351 
food intake [44, 59]. In solubility studies of two lipophilic bases, dipyridamole and 352 
ketoconazole, it was shown that milk digested with the HCl solution of pepsin gave a good 353 
prediction of the ketoconazole’s solubility in human gastric aspirates after administration of 354 
500 mL of Ensure® Plus while a solubility overestimation was observed for dipyridamole. 355 
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When milk digested with pepsin/HCl/lipase was used the prediction of the drug’s solubility in 356 
the gastric aspirates was dependent on the time that the in vivo sample was collected [44]. The 357 
biorelevance of the addition of lipase in the milk in terms of pH and protein content was shown 358 
in a release study of felodipine from an extended release matrix. Gastric pH decreased slower 359 
and protein content faster than an identical medium in the absence of lipase, giving pH and 360 
protein content values closer to the ones observed in vivo [13].  361 
 362 
 Fed State Simulated Gastric Fluid (FeSSGF) 363 
As an effort to improve the biorelevance of milk as dissolution medium and simulate 364 
the postprandial conditions of the gastric tube, a medium called Fed State Simulated Gastric 365 
Fluid (FeSSGF) was developed. This medium was developed by Jantratid and his co-workers 366 
[37] and is comprised of 3.5% fat milk diluted with acetate buffer. In order to mimic the three 367 
phases of gastric digestion with the pH value being 6.4, 5.0 and 3.0 for the early, middle and 368 
late phases, respectively, a FeSSGF for each phase was prepared (Table 4) [37]. The pH was 369 
adjusted with the use of 0.1 N HCl and NaOH solutions and it was suggested that the “middle” 370 
medium reflects in a satisfactory manner the sum of the physiological gastric conditions during 371 
meal ingestion. Accepting this compromise, FeSSGF could potentially be used as a universal 372 
medium potential for fed-state gastric dissolution [37]. It should be noted though that this 373 
medium does not contain any enzymes, so the presence of the gastric pepsin and lipase are not 374 
taken into account. As milk in the absence of enzymes can only simulate the gastric fed state 375 
condition in its early phase [8], the use of the three “snapshot” media can simulate the 376 
intraluminal changes in pH, osmolality and protein contents accurately.  377 
 378 
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5.2. Nutrient drinks/Emulsions 379 
 380 
The use of various nutrient drinks and emulsion for parenteral administration have been 381 
employed to studies as an attempt to mimic the gastric stomach conditions in the fed-state, as 382 
they have similar composition (Table 5) to the standardised meals used in drug food effect 383 
studies [6].  384 
Scandishake Mix® is a nutrient drink used for the simulation of gastric environment in 385 
the fed state. It was used in the form of powder mixed with whole milk with simulated gastric 386 
secretions containing lipase and pepsin in a dynamic in vitro system (TNO TIM-1), simulating 387 
the stomach and small and large intestines’ environment. Scandishake mix® was used for the 388 
simulation of a high-fat meal in the development of a dissolution model for fosamprenavir 389 
(prodrug of the antiretroviral aprenavir) [61]. Food-induced disintegration of fosamprenavir’s 390 
tablets was assessed using Magnetic Resonance Imaging (MRI). The stomach compartment in 391 
the dynamic system was comprised of two units separated by a silicon wall with the surface 392 
between the outer and inner tubes being thermostated (37 °C). The simulated gastric contents 393 
were mixed by application of water pressure to the walls, causing three “contractions” and 394 
“relaxations” per minute. Simulated gastric lipase and pepsin were pumped to the compartment 395 
at a flow of 0.5 mL/min. The nutrient drink, compared with simulated gastric fluid (SGF), 396 
which was used for the gastric fasted state simulation, predicted the formulations’ proprandial 397 
delay in disintegration observed in vivo. This effect on the tablet’s disintegration can be 398 
attributed to the competition of the nutrient drink with the water molecules for the interaction 399 
with the matrix and by the formation of a water layer of increased viscosity around the tablet 400 
[61].  401 
The nutrient drinks Ensure® [62] and Ensure Plus® [13, 62] have been used in several 402 
studies as biorelevant fed–state gastric media. According to the manufacturer [63], both 403 
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emulsions contain water, corn maltodextrin, sugar, milk protein concentrate, canola oil and 404 
corn oil (Ensure® Plus) or soy oil and sucromalt (Ensure®). Intralipid®, an emulsion for of 405 
similar fat content with Ensure® and Ensure Plus®, has also been used for the simulation of 406 
gastric fed state conditions after the administration of a high-fat breakfast [10]. Ensure® 407 
contains fat (3.7%), protein (3.7%) and carbohydrate (14.5%), while Intralipid® is available in 408 
10, 20 and 30% fat concentrations (soya oil), with the emulsion also containing egg lecithin 409 
protein (12 g/1000 mL) and glycerol (22, 22 and 16.7 g/1000 mL for 10, 20 and 30% fat, 410 
respectively. Ensure® and Intralipid® 10% were used at a 1:6 dilution with universal buffer (pH 411 
2.5 and 5.6) in dissolution (USP Apparatus 2, 100 rpm) and microcalorimetry studies of 412 
aminophylline controlled release tablets comprised of an aliphatic alcohol and 413 
hydroxyalkylcellulose [68]. Each dissolution profile was the expression of two distinct 414 
processes; dissolution of the alcohol and diffusion of the drug though the cellulose derivative. 415 
The profile was comprised of two first order rates separated by a mixed rate. The composition 416 
of the biorelevant medium mainly affected the rate of the initial first-order process and also the 417 
onset time of the second apparent first order, indicating that differences in the medium can 418 
affect the drug release mechanism.  419 
The similarities of the physicochemical properties (pH, osmolality, buffer, capacity, 420 
viscosity and surface tension) between standard meals used in in vivo studies and gastric fed 421 
state media used in vitro have been assessed [43]. Ensure Plus® demonstrated better 422 
resemblance to the gastric conditions after the administration of a homogenized standard 423 
breakfast than milk and Ensure® but had significantly different viscosity, an issue resolved after 424 
addition of 0.45% w/v pectin, a water soluble polysaccharide. In vitro dissolution studies 425 
performed with Ensure® (USP Apparatus 2) [62] and Ensure Plus® [64] (USP Apparatus 3) 426 
demonstrated that dissolution behavior is greatly affected by interaction between medium 427 
component and formulation. In the above studies, food effect observed in vitro was attributed 428 
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to a formation of a hydrophobic layer around the formulation (HPMC matrix) decreasing water 429 
ingress in the tablet [64], or by granting a more effective hydration of a matrix component [62].  430 
Another nutrient drink, Nutrison®, was used for the simulation of gastric fed state 431 
conditions in dissolution studies (USP Apparatus 2, 100 rpm) for the study of possible food-432 
drug interactions between food components and metoprolol tartrate IR tablets [5]. The nutrient 433 
drink contains 6 g/100 mL protein, 6 g/100 mL vegetable oil fat, 18 g/100 mL carbohydrate, 434 
vitamins and minerals. For its use as a biorelevant medium it was diluted to 60% with a solution 435 
containing HCl, NaCl, KCl and sucrose, giving values of pH (pH= 5.4) and osmolality (420 436 
mOsm/kg) similar to the in vivo fed state conditions. A potential excipient dependent 437 
mechanism of delay in tablet disintegration was indicated through the formation of a protein 438 
film from the medium’s components around the tablets (visual observation) attributed to 439 
electrostatic or hydrophobic interactions between the proteins and the excipient a confirmed by 440 
scanning electron microscopy (SEM). The dependence of the formation of this layer on certain 441 
tablet excipients was confirmed by preparation of single excipient-medium mixtures and 442 
observation of a precipitation layer in the vessel for each mixture. The effect of meal type was 443 
further evaluated by comparing tablet disintegration times in media containing a single 444 
(protein, fat or carbohydrate) or mixtures of the mentioned components present in the fed state 445 
medium. The presence of proteins increased the tablet disintegration time the most, with a more 446 
profound effect when proteins were combined with fat, carbohydrates or both.  447 
Even though the composition of nutrient drinks like Ensure Plus® is more similar to the 448 
high-fat meals administered in BA/BE studies, milk based media can simulate the fed gastric 449 
content taking the presence of secretions into consideration [65]. Moreover, with the two 450 
approaches mentioned before (gradual digestion and snapshot media), the changes in the fed 451 
gastric environment during time can be more closely simulated.  452 
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Another version of the FeSSGF “snapshot” media has been recently proposed replacing 453 
milk with Lipofundin® MCT 20, [66] an emulsion administered parenterally to patients, 454 
providing essential fatty acids. The emulsion: buffer ratios were different to those of the milk 455 
based FeSSGF “snapshot media” (17.5, 8.75 and 4.375% v/v content for early, middle and late 456 
media, respectively compared to 100, 50 and 25% for the milk-based media). Lipofundin® does 457 
not contain any proteins, which facilitates the drug’s analysis in the medium and has similar 458 
fat content to the fed stomach aspirates [67]. 459 
 460 
6. Drug and formulation-related food effect 461 
 462 
Under fed state conditions, tablet disintegration is generally delayed. For example, as 463 
mentioned previously, a nutritional drink used both in in vivo (canine) and in in vitro studies 464 
delayed disintegration and dissolution of metoprolol tartrate tablets by creating the formation 465 
of a food- induced thin layer around the tablet which not only did prevent the water penetration 466 
in the tablet but also the drug particles from leaving the matrix. [5].  467 
 Food can have a significant effect on the absorption of drugs. This can be affected by 468 
differences in the interaction of the active pharmaceutical ingredient or/and the formulation 469 
with the fasted and fed state environments. Examples of two drugs (itraconazole and 470 
nifedipine) demonstrating drug-related and formulation-related gastric food effect, 471 
respectively, are discussed below.  472 
 Itraconazole, an antifungal agent, is a well-studied drug in terms of its food effect. The 473 
positive effect of food on itraconazole’s absorption has been verified by both in vivo and in 474 
vitro studies. An in vivo study on itraconazole capsules (2 × 100 mg capsules administered) 475 
containing sugar coated pellets in healthy subjects was performed with the use of the FDA 476 
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standard breakfast for the determination of the drug’s food effect [68]. The study showed a 477 
significant increase for both Cmax and AUC0→∞ values (Cmax(fasted) = 0.59 Cmax(fed), AUC0→∞ (fasted) 478 
= 0.61 AUC0→∞ (fed) ) (Figure 3) with the increase in the drug’s absorption being attributed to 479 
the drug’s increased solubility in the food components. A similar study by Zimmermann et al. 480 
[69], (one 100 mg capsule administered with a standard breakfast) demonstrated similar results, 481 
with the relative bioavailability in the fasted state being 0.54 times the one observed after meal 482 
administration. The differences were attributed to the high-fat content of the meal and also to 483 
the longer gastric retention time in the fed state. 484 
In vitro studies were in agreement with the fact that the drug’s bioavailability could be 485 
significantly affected by food [70]. An in vitro study used milk of different fat concentrations 486 
mixed with simulated gastric fluid (SGF) (pH adjusted to 3) as fed state biorelevant dissolution 487 
media and demonstrated that except for fat, other food components may be responsible for the 488 
food effect observed with itraconazole in vitro. Despite a pronounced difference between 489 
dissolution rates in the fasted (SGF pH 3) and the fed state simulated media, the fat content did 490 
not lead to statistically significant dissolution rates among the milk-based media. The presence 491 
of different carbohydrates (1% w/v glucose, lactose and starch in SGF) increased the 492 
dissolution rate at a small extend, possibly by formation of hydrogen bonds between the drug 493 
and the carbohydrates’ hydroxyl functional groups. On the contrary, increased protein content, 494 
appeared to have a positive effect of drug dissolution. Drug dissolution rates in media 495 
containing albumin (0.5-4% w/v) concentration in SGF, increased by increasing the protein 496 
content. One possible mechanism could be through protein-drug binding possibly by the 497 
development of electrostatic and lipophilic interactions between the drug and albumin.  498 
Nifedipine is a calcium channel blocker with a complicated formulation-related food 499 
effect [5]. Immediate release tablets, prolonged (modified) release tablets, capsules and soft 500 
capsules of nifedipine (5–60 mg) are commercially available [71]. Significant differences in 501 
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the bioavailability of nifedipine modified – release formulations after oral administration have 502 
been observed in vivo between fasted and fed state conditions [72, 73]. The bioavailability of 503 
the brand formulation, Adalat OROS® (Osmotic-Release Oral System), has not been 504 
significantly affected by the presence of food [72, 74, 75]. Dose dumping and unusually long 505 
lag times, possibly due to lack of robustness of the mechanism of drug release in the fed state 506 
or due to prolonged stay of the formulation in the stomach, have been observed after 507 
administration of generic nifedipine formulations. During the gastric residence of nifedipine, 508 
the rate of absorption is limited, which led to rapid and high absorption when it reached the 509 
small intestine, altering the formulation’s controlled release mechanism characteristics of some 510 
generic formulations [76, 77]. Nifedipine Sandoz® retard 30 mg, (eroding matrix system) [74], 511 
Nifedicron® 60 mg, (capsule with mini-tablets, Pharmatec International, Milano, Italy)] [75], 512 
Slofedipine® XL 60 mg (eroding matrix system) [72] and Nifedipine ER 90 mg test tablet 513 
(hydrophilic matrix, pilot formulation, Astra AB, Sweden,) [78] demonstrated a formulation 514 
induced food effect after co-administration with a high-fat standard breakfast. Nifedipine 515 
Sandoz® retard demonstrated significant differences in its pharmacokinetic behavior between 516 
fasted and fed states, possibly due to the inability of the matrix to release the drug in a 517 
controlled way, with the exact mechanism not having been experimentally proven [76]. Dose 518 
dumping and a three-fold increase of the Cmax was observed for Nifedicron
® under the fed state 519 
conditions compared to the fasted state [75]. Slofedipine® XL’s profiles between the fasted and 520 
the fed state (high-fat breakfast) were also significantly different. Nevertheless, even though 521 
the geometric AUC0→24 mean in the fed state was approximately half the one in the fasted state 522 
for Slofedipine® XL, the AUC0→tn values were identical [72].
 Similar behavior was observed 523 
with Nifedipine ER tablets (90 mg), which demonstrated a higher absorption rate than 524 
Procardia® XL (90 mg) (osmotic pull-push system tablet), which was used as a reference 525 
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product. The effect was attributed to the increased erosion rate as a result of the gastric motility 526 
and alterations in the gastric content after meal administration [78].  527 
It is worth mentioning that in several of the above studies, differences in the fed state-528 
pharmacokinetic behavior between the brand and generic formulations have also been 529 
observed. In the case of nifedipine Sandoz® retard, great inter-patient variability often 530 
accompanied with fast, uncontrolled drug release was observed in plasma concentration vs time 531 
profiles, demonstrating failure of the controlled release behavior of the formulation under fed 532 
conditions [74]. In case of Slofedipine® XL [72], the authors concluded that the differences 533 
between the test (Slofedipine® XL) and the reference (Adalat® OROS) formulations in the fed 534 
state could be attributed to the prolonged transit time of the former. Slofedipine® XL had a 535 
significant delay on the onset of its therapeutic action in 15 out of 24 patients of the study (15h 536 
lag time), which resulted in 29% decreased AUC0→tn compared to Adalat
®. Slofedipine® XL’s 537 
lag time was attributed to the fact that undissolved particles of the formulation of a diameter 538 
above 10 mm were not able to pass through the pylorus, until the onset of phase III of the 539 
migrating motor complex (MMC; the cylindrical series of gastric electrical activity, taking 540 
place between meals) [79]. In the same study, in vitro dissolution studies in acetate buffer pH 541 
4.5 demonstrated that at pH values similar to the fed state, the generic formulation remained 542 
undissolved for 24 hours, in contrast to Adalat® OROS which was almost 100% dissolved.  543 
 544 
7. Meal– related food effect 545 
 546 
Drug food effect relates to the nature of the meal. Meal characteristics such as fat 547 
content, viscosity, caloric content size, and volume are parameters which can affect its 548 
absorption.  549 
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Increased fat content in the fed state relates to delayed drug absorption due to slower gastric 550 
emptying rate [23] and to decreased drug dissolution due to retarded wetting of the formulation 551 
[80]. Increased viscosity of the gastric contents due to the administered meal delays the rate of 552 
gastric emptying [81]. Increased meal viscosity can decrease the diffusion coefficient of a 553 
compound according to Stokes-Einstein equation [82], which could in turn decrease drug 554 
absorption if it is only absorbed in a specific part of the gastrointestinal tract, as the drug goes 555 
past this site. The effect of meal viscosity is impaired in the small intestine due to secretions 556 
and digestion products. The most common effect of high meal viscosity is an increase in the 557 
Tmax values of drugs. In an in vivo study using canine subjects, when a calorie free viscosity 558 
enhancer, HPMC (hydroxypropylmethylcellulose), was added, a delay in the Tmax of the 559 
antiarrhythmic bidisomide was observed [83]. The meal’s residence time depends also on its 560 
caloric content [26]. 2-4 kcal of caloric content per minute are transferred to the duodenum 561 
[17], meaning that meals with high caloric content will reside in the stomach for longer periods, 562 
affecting drug’s transit time in the gastrointestinal tract. Nutrient drinks of 1 kcal/mL content 563 
are emptied at a rate of 2-2.5 mL/min, while nutrient drinks of 0.2 kcal/mL content have an 564 
emptying rate of 10 mL/min [17]. A calorie-dependent decrease of the gastric emptying rate 565 
was observed for the solid portion of the meal (45± 3.4% of the meal mass retained in the 566 
stomach for the 68 kcal solid meal and 65± 4% for the 633 kcal solid meal at 100 min), while 567 
its liquid portion is emptied to the duodenum at a rate independent of its energy content [11]. 568 
Meal size and volume relate to its gastric residence time [11]. Meals of fourfold mass and 569 
similar caloric content resulted in a 388% higher emptying rate, attributed to activation of 570 
stretch or volume receptors in stomach, increasing peristalsis. Using different volumes of 571 
isocaloric meals, a statistically significant increase in gastric emptying rate with the larger 572 
volume was noted for volumes of liquid meals between 200 mL and 800 mL [84]. 573 
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8. Analytical techniques and challenges for sample treatment and drug 574 
quantification  575 
 576 
Most of the gastric fed state media used until now are milk based or o/w emulsions; 577 
therefore, several sample preparation processes have been developed for the extraction of the 578 
drugs from these matrices. Milk is a complex biological fluid containing proteins, lipids, 579 
carbohydrates, divalent and trivalent cations which can be bound to the compounds of interest 580 
making drug analysis challenging. The analytical techniques, issues and challenges described 581 
in this section refer mainly to fed state gastric biorelevant media which are at least partly 582 
comprised by milk or contain other types of lipid and protein sources. The quantification of 583 
drugs in these media is usually performed using high performance liquid chromatography 584 
(HPLC) and therefore, the analytical challenges and problems presented below refer mainly to 585 
this technique. 586 
 587 
8.1. Filtration 588 
 589 
The first challenge with drug analysis when biorelevant media are used is filtration 590 
itself. Filtration is an essential step in the analytical procedure, as biorelevant media contain a 591 
range of particles deriving from lipids, carbohydrates, fat and salts, which have to be removed 592 
before the sample’s injection in the HPLC. Moreover, when fed biorelevant media like milk or 593 
FeSSGF are used, the use of small pore size filters for the sample analysis during solubility or 594 
dissolution studies cannot be used due to clogging from the presence of large proteins [9]. 595 
Several types of filters like 0.45 or 0.22 μm polytetrafluoroethylene (PTFE) [64] or regenerated 596 
cellulose (RC) [44] have been used for sample analysis prior to HPLC injection for drug 597 
quantification in both milk and lipid-based media but a sample cleanup step is required before 598 
for these type of media. Glass microfiber (GF) 2.7 μm filters have also been used in drug 599 
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solubility and dissolution studies in milk based media [85], in order to remove undissolved 600 
drug or formulation particles prior to sample treatment and filtration through the filters of 601 
smaller pore size. Filters of bigger pore size, attached to the sampling cannulas of the USP 602 
Apparatus 1/2 (polyethylene sticks, 10 μm and nylon membrane filters, 5 μm) have also been 603 
used in dissolution studies with FeSSGF and milk for the same reason [56, 85]. 604 
Adsorption of the analyte on the filters should be studied in order to evaluate and choose 605 
the appropriate filters. Salicylic acid and sodium saccharine are example of drugs which 606 
demonstrate significant adsorption on Nylon filters as shown in a study by Carlson et al. [86], 607 
where 85.8% and 60.4% of salicylic acid at 0.005 mg/mL and 0.05 mg/mL concentrations 608 
respectively was adsorbed on 25 nm nylon filters. Sodium saccharine demonstrated even higher 609 
adsorption with the entire drug (100%) being adsorbed on the same filters at a 0.1 mg/mL 610 
concentration [86, 87]. It should be noted that if the first few drops of the filtrate are not 611 
discarded, the percentage of adsorption can reach extremely high values.   612 
 613 
8.2. Medium 614 
 615 
The analysis of the drug content in milk based media can be challenging as the content 616 
of the medium itself is comprised of a lipid and an aqueous phase that requires separation of 617 
the phases before an HPLC analysis can be performed. Analysis could be affected by the 618 
differential distribution of the drug in the multiple phases of the milk based media, as it could 619 
distribute either in the aqueous or lipid phase or even bind to the proteins or fat contained in 620 
the medium. Several drugs have shown binding in milk at amounts higher than 50%; diazepam, 621 
indomethacin, grizeofulvin and dicumarol demonstrated binding percentages from 622 
approximately 55% to 95% in low and full fat milk (37 °C) after equilibrium dialysis against a 623 
phosphate buffer solution (pH 6.5). For some drugs, their percentage bound was more 624 
significantly affected by milk’s temperature (dicumarol, prednisolone) and fat content (e.g. 625 
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binding of diazepam increased more than 13% in full fat milk in comparison to low fat milk at 626 
temperatures 15–37 °C) [88]. A factor affecting the analysis of milk is its variable fat, 627 
carbohydrate and lipid content. Its composition differs among different mammalian species, 628 
and is also affected by parameters such as their diet or the onset of their lactation period [89]. 629 
Therefore, milk of the same commercial brand and batch should be used when different drugs 630 
and dissolution conditions are compared, as changes in the medium composition may affect 631 
parameters like recovery, precision, and analytical method compatibility.  632 
 633 
8.3. Sample treatment and analysis 634 
 635 
i. Protein precipitation 636 
One simple method of sample cleanup prior to drug quantification in gastric milk- based 637 
fed state media is protein precipitation. Protein precipitation is the technique mainly used until 638 
now with the addition of a volume of an organic reagent to a volume of medium, followed by 639 
a centrifugation and a filtration step before its analysis in HPLC. The precipitation of the milk’s 640 
proteins can be performed using an organic reagent followed by filtration and centrifugation 641 
steps [9].  642 
A range of solvents like acidified MeOH [90], acetone [91] and HCl [92] have been 643 
used as protein precipitation reagents for the extraction of drugs from milk-based media. 644 
Parameters such as their compatibility with the analytical technique chosen, their volatility in 645 
case organic phase evaporation is needed, their selectivity and their cost have to be considered 646 
during the selection of an appropriate protein precipitation solvent [88]. 647 
Fotaki et al. [60] suggested a precipitation and centrifugation method for the 648 
quantification of L-sulpiride, a BSC class III drug, in a milk based dissolution medium, 649 
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proposing an assay involving centrifugation at 4000 rpm for 10 min (8 ºC) for the separation 650 
of the aqueous phase from the lipid phase with acetonitrile being added in the aqueous filtrate 651 
(1:2) and a last centrifugation and filtration step (Titan® filters 0.45 µm) following. Sample 652 
treatment in nutrient drinks and emulsions requires a more time consuming cleanup procedure. 653 
Ensure® Plus requires phase separation via a centrifugation step (e.g. 11500 rpm, 1.5 h) [64] 654 
and possibly an extra filtration step with a larger pore size filter (5 μm) prior to filtering with a 655 
0.45 μm filter and injecting the supernatant in the HPLC.  656 
A study by Williams et al. [10] used 1:2 with ice-cold 12% (w/v) trichloroacetic acid 657 
for milk protein precipitation and then centrifugation at 10000 rpm for 15 min extracting 0.2 658 
mL of the supernatant for the HPLC analysis [10] for the quantification of caffeine in both 659 
milk-based (0.1%, 1.7%, 3.6% fat milk) and fat emulsion type (30% fat emulsion (Intralipid®)) 660 
media. Despite the fact that a protein precipitation step, followed by centrifugation and 661 
filtration, was adequate for both types of media, the recovery of the drug in the fat emulsion 662 
was significantly lower. A challenge associated with the selection of protein precipitation 663 
reagents is their compatibility with the HPLC method for the analysis of the selected drug. 664 
Peak fronting is a common issue when organic reagents of higher strength than the mobile 665 
phase are used; an issue which can usually be resolved with evaporation of the reagent under 666 
nitrogen and reconstitution in the mobile phase. Another disadvantage of this technique is its 667 
inability of complete removal of the lipid part of the medium [89], as for the selective removal 668 
of lipids, a supplementary step is required. This step may be a wash with hexane, given that the 669 
compound of interest is ionised or not extracted in hexane, so as not to be lost during the 670 
washing step [93].  671 
 ii. Solid Phase Extraction (SPE) 672 
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 Another method used for the extraction of the analyte of interest from milk is Solid 673 
Phase Extraction (SPE). Solid phase extraction (SPE) is widely used for the extraction of drugs 674 
from biological fluids such as whole blood [94], plasma [95], urine [96] and milk [97], and is 675 
often preceded by a protein precipitation step. SPE cartridges are comprised by a polypropylene 676 
tube with their sorbent between two porous frits. A typical experimental protocol involves 4 677 
main steps: i. cartridge conditioning, ii. sample loading, iii. sample washing and iv. sample 678 
elution [98]. 679 
Most cartridges are either comprised of bonded silica phases, similar to the material of 680 
the reversed phase HPLC columns but with bigger diameter particles (10–60 μm), or of 681 
polymeric resins (e.g. polystyrene-divinylbenzene). [99] SPE C18 cartridges have been used for 682 
the quantification of several drugs, like β-lactam antibiotics [100] or nonsteroidal anti-683 
inflammatory drugs (NSAIDs) [101], in milk. In the above studies, a protein precipitation step 684 
similar to the one previously described [60] took place before the extraction, due to the milk’s 685 
high content in proteins and lipids, which render the sample too “dirty” to be loaded straight 686 
on the cartridge. An elution solvent of high water percentage is preferable for extraction from 687 
milk-based media, and has to be able to elute the drug and retain most of the lipids on the 688 
cartridge [10]. The extraction yield of lipid drugs using SPE may be low due to the drug’s 689 
interaction with milk’s fat globules. A way to disrupt this drug-fat globule interactions would 690 
be sonication and dilution of the medium before its loading on the cartridge [89]. A challenge 691 
for the analysis with SPE when it comes to biorelevant media, is the interference from the 692 
matrix in HPLC analysis. Therefore, cleanup with a solid phase extraction cartridge can help 693 
towards the development of more sensitive and robust methods in drug analysis in fed state 694 
biorelevant media. Disadvantages of SPE as a drug’s extraction method from gastric fed state 695 
media include the quick drying of the cartridges and the difficulty to adjust the vacuum during 696 
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the multiple steps without the presence of an automated manifold, affecting the reproducibility 697 
of the method [102, 103]. 698 
iii. Liquid-liquid extraction (LLE) 699 
 Liquid-liquid extraction is based on the analyte partitioning between an aqueous phase 700 
and a water-immiscible solvent [99]. Several extraction protocols have been successfully 701 
applied for a wide range of drugs such as mycotoxins [104], mycrocyclic lactones [105], 702 
vitamins [106] and analgesics [107]. The main advantages of LLE is the short time required 703 
for method development and its low cost. A serious drawback is the fact that it is a time- 704 
consuming and labour intensive method. Moreover, the possible presence of the milk’s lipid 705 
content in the extraction solvent after the LLE process, leads to phase separation of the sample 706 
and lipid partitioning in the stationary phase of the HPLC column during drug analysis. 707 
Therefore a washing step with hexane is usually required, so as to remove the lipids [89], 708 
making the whole procedure even more time consuming. The following protocol used in milk 709 
for the quantification of Ochratoxin A is a typical case of liquid-liquid extraction [104]; 0.2 710 
mL saturated NaCl solution and 2.4 mL chloroform were added to 1 mL milk, mixed gently 711 
for 3 minutes, centrifuged (4500 rpm, 20 minutes) and after the removal of the chloroform 712 
layer, evaporation to dryness under nitrogen steam and reconstitution in acetonitrile followed. 713 
Lipid removal was performed by double extraction (2 × 0.4 mL petroleum ether for 1 min). 714 
After discarding the etheric layer, acetonitrile was blown to dryness, reconstituted in 1 mL of 715 
mobile phase, filtered and analysed in HPLC.  716 
iv. Ion Selective Electrode (ISE) sensor 717 
An online monitoring system, in an attempt to avoid the sample treatment traditionally 718 
required for the extraction of the analytes of interest from FeSSGF has been published [9]. An 719 
Ion Selective Electrode (ISE) sensor system was used, with two electrodes placed constantly 720 
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in the dissolution vessel which were able to monitor the changes in drug concentration through 721 
the changes in potential. With this proposed methodology, diphenhydramine hydrochloride 722 
was successfully quantified in a dissolution study using the USP Apparatus 2 in several fasted 723 
[Fasted State Simulated Gastric Fluid (FaSSGF), Fasted State Simulated Intestinal Fluid 724 
(FaSSIF) and Fasted State Simulated Intestinal Fluid Version Two (FaSSIF-V2) and fed 725 
(FeSSGF) state biorelevant media. Sample preparation steps needed with extraction techniques 726 
were avoided, and a continuous dissolution profile and a much faster and less laborious 727 
alternative were offered. Disadvantages of this method are: a. its limitation to the analysis of 728 
ionised drugs b. the complicated correction of the baseline needed for the heterogeneous 729 
biorelevant media and c. its inability for the analysis of compounds of extremely low aqueous 730 
solubility [9]. 731 
 732 
v. Other techniques 733 
Several other techniques have been used for drug quantification in milk and may have 734 
the potential to be used in fed state gastric media, some of which are briefly listed below: 735 
Matrix solid-phase dispersion (MSPD): The matrix solid-phase dispersion (MSPD) 736 
technique was firstly developed by Barker et al. [108]. MSPD involves the grinding of 737 
biological samples with sorbent particles producing a column material acting as a solid support 738 
from which the drugs in the matrix can be selectively extracted [109, 110]. MSPD has been 739 
successfully used in drug quantification in milk with sorbents, like C18 [111], C8, silica gel 740 
[112], mixed-mode/cationic-exchange (MCX), mixed-mode/anion-exchange (MAX) and weak 741 
anion–exchange (WAX) [113], and more recently molecularly imprinted polymers (MIPs) 742 
[110]. An advantage of this method is the combination of homogenization, fractionation and 743 
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purification in one single step and could be also used to milk-based gastric dissolution media 744 
[109]. It is also cheap and environmentally safe but relatively labour demanding [114].  745 
Solid-phase microextraction (SPME): SPME is a sample preparation technique 746 
which is based on a concentration equilibrium between an extracting phase associated with a 747 
solid support and a biological matrix [115]. Two different SPME designs are the most 748 
commonly used: in-tube mode and fibre design. In this technique, small quantities of the 749 
sorbent are exposed to the headspace or solution of the biological sample using a suitable 750 
format. After a predefined amount of time and when equilibrium between the coating and the 751 
matrix has been reached, the sorbent does not absorb any additional quantity of the analyte of 752 
interest, meaning that the amount of drug extracted for a specific concentration is constant 753 
[116]. The main advantages of SPME are its low cost and the fact that it is time saving and 754 
environmentally friendly [117]. Some of its disadvantages are the slow time for equilibrium 755 
between the analyte and the extraction phase to be reached [118], the poor selectivity and the 756 
limited type of fibres commercially available [119]. 757 
Ultrafiltration: Ultrafiltration is a technique extensively used in food industry and 758 
water treatment. It is based on the selective passage of drugs of low molecular weight through 759 
the pores of a membrane of a specific MW cut-off, which inhibits the passage of molecules of 760 
higher MW. This technique does not involve time-consuming steps but its use is limited by 761 
reduced sensitivity due to interferences from the matrix in drug analysis and is usually used in 762 
combination with other cleanup techniques [89]. Ultrafiltration was successfully employed for 763 
the quantification of tetracyclines in milk, by adding solid EDTA at 10 mM concentration, 764 
before sample centrifugation at 5000 rpm for 1 hour. Ultrafree MC/PL devices (nominal 765 
molecular weight limit 5000) were used in this study [120]. 766 
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 9. Conclusion 767 
 768 
Prediction of gastric food-effect of drugs has been a challenge of the pharmaceutical 769 
industry. Even though the in vivo properties of the fed state gastric environment have been 770 
determined in some cases, the complicated fed environment due to differences in the meals 771 
administered makes the determination of the precise gastric conditions difficult. Despite the 772 
fact that some progress has been made with the development of gastric biorelevant media, a 773 
universal robust predictive analytical method has not been yet developed. The development of 774 
suitable biorelevant media in combination with a simple and robust analytical method could 775 
potentially provide a means of understanding of a potential food effect in regards of a drug’s 776 
solubility and dissolution. Several biorelevant dissolution fed state media like milk, nutrient 777 
drinks or Fed State Simulated Gastric Fluid (FeSSGF) have been developed in an attempt to 778 
simulate the human postprandial conditions. Nevertheless, none have managed to achieve 779 
precise representation and fully overcome issues such as the need of a time consuming 780 
preparation for the quantification of the drug, possible matrix interferences and compatibility 781 
with the analytical methods used.  782 
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List of Tables 1259 
Table 1. Physicochemical Properties of the contents of the fed state stomach based on in vivo 1260 
measurements. 1261 
pH 
Value 
Technique 
employed 
Meal Sample Reference 
6.23–6.84 
(during meals 
and 1-2 hours 
after meal 
administration) 
Bravo 
wireless pH 
monitoring 
capsule 
No 
restriction 
in meal 
composition 
11 
volunteers 
(8 
healthy) 
[31] 
median 6.4–
2.7 (from 5 
min to 3h 
30min) 
Aspiration 
through 
nasogastric 
tube  
500 mL 
Ensure 
Plus® 
20 healthy 
volunteers 
[13] 
median 5.0 
(peak 6.7) 
Heidelberg 
capsule 
Standard 
meal 1000 
kcal 
34 healthy 
volunteers 
[28] 
Osmolality 
559 mOsm kg-1 
- 217 mOsm 
kg-1, (from 30 
to 210 min) 
Aspiration 
through 
nasogastric 
tube /freezing 
500 mL 
Ensure 
Plus® 
20 healthy 
volunteers 
[13] 
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point 
depression 
Buffer 
capacity 
14-28 mmol L-
1 DpH 
 (from 30 to 
210 min) 
Aspiration 
through 
nasogastric 
tube /titration 
with HCl 
500 mL 
Ensure 
Plus® 
20 healthy 
volunteers 
[13] 
Surface 
tension 
30-31  
mN m-1 
Aspiration 
through 
nasogastric 
tube /titration 
with HCl 
500 mL 
Ensure 
Plus® 
20 healthy 
volunteers 
[13] 
 1262 
  1263 
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Table 2. Biopharmaceutics classification system, predictability of food effect and transporter 1264 
effect [46, 48]. 1265 
BCS 
class 
Solubility/ 
permeability 
Food 
effect 
Drug 
examples 
Transporter 
effect on 
drug 
disposition 
Transporter effect by 
high fat meal 
I +/+ 
no 
effect 
Disopyramide 
Ketoprofen 
Verapamil 
Minimal No effect 
II -/+ + 
Cyclosporine 
Danazol 
Dapsone 
Efflux 
transporter 
effects 
predominate 
Efflux transporters inhibition, 
intestinal drug solubilisation 
(drug passively absorbed) 
Inhibition of both absorptive 
and efflux transporters. Food 
effect according to relative 
inhibition (drugs actively 
absorbed) 
III +/- - 
Fesofenadine 
Nadolol 
Valsartan 
Absorptive 
transporter 
effect 
predominate 
Inhibition of absorptive 
transporters in the intestine 
IV -/- +, -,  
Chlorothiazide 
Furosemide 
Possible 
substrates for 
both 
All effects mentioned above 
for classes II and III 
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no 
effect 
Neomycin absorptive 
and efflux 
transporters 
 
1266 
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Table 3. Examples of meals used in for the determination of drug- food interactions in vivo. 1267 
Meal  Composition Fat content Protein content Carbohydrate content Reference 
GSK high-fat 
standard meal  
2 slices of toasted white bread with butter, 
2 eggs fried in butter, 2 slices of bacon, 2 
ounces of hash browned (fried shredded) 
potatoes, 8 ounces of whole milk 
 67 g (603 
kcal, 62% of 
total calories) 
33 g (132 kcal, 
14% of total 
calories) 
58 g (232 kcal, 24% of 
total calories) 
[43] 
FDA high-fat 
standard meal 
2 eggs fried in butter, 2 strips of bacon, 2 
slices of toast with butter, 4 ounces of hash 
brown potatoes, 8 ounces of whole milk 
(800-1000 kcal) 
500-600 kcal  150 kcal  250 kcal  [51] 
FDA 
intermediate-fat 
standard meal 
1 English muffin with butter, 1 fried egg, 1 
slice of cheese, 1 slice Canadian bacon, 1 
serving of hash browned (fried shredded 
potatoes), 6 ounces of orange juice, 8 
ounces of whole milk 
27 g, (240 
kcal, 37 % of 
total calories) 
29 g (116 kcal, 
18% of total 
calories) 
73 g (292 kcal, 45% of 
total calories) 
[43] 
Light 
standardised 
breakfast 
Not specified (+100 mL of black coffee) 
 
26 g 28 g 51 g [121] 
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Standardised 
high-
carbohydrate 
meal 
Not specified (1000 kcal) Not specified Not specified 600 kcal  [122] 
Low-fat meal 1 slice of white spread bread with jelly, 6 
ounces of orange juice, 8 ounces of skim 
milk (250 kcal) 
1 g  12 g 51 g [83] 
Long chain 
truglyceride meal 
Fat: 80% w/w medium chain triglycerides 
(C6-C12) 
Proteins: whey, casein and soy hydrolysates 
Carbohydrates: monosaccharides, 
oligosaccharides, polysaccharides 
36% of total 
calories 
16% of total 
calories 
48% of total calories [123] 
Medium chain 
triglyceride meal 
Fat: 31% w/w medium chain triglycerides 
(C6-C12) 
Proteins: whey, casein and soy hydrolysates 
Carbohydrates: monosaccharides, 
oligosaccharides, polysaccharides 
36% of total 
calories 
16% of total 
calories 
48% of total calories [123] 
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 1268 
a 25 °C 1269 
b 37 °C 1270 
*Calories derived from fat 1271 
 1272 
  1273 
High-protein meal 2% low fat milk, Carnation Instant 
Breakfast® and Pro Pac® Plus (protein 
supplement) 
9 g 80 g 52 g [53] 
High-protein meal Not specified (439.5 kcal) 17.1 g 30.5 g 43.5 g [124] 
Low-protein meal Not specified (417.8 kcal) 14.9 g 10.5 g 64.3 g [124] 
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Table 4. Physicochemical properties of gastric fed state biorelevant media used in vitro. 1274 
Medium Mass (g) 
Volume 
(mL) 
Density 
(g/ mL) 
pH 
Buffer capacity 
(mEq pH-1 L-1) 
Osmolality 
(mOsmol kg-1) 
Surface 
tension 
(mN m-1) 
Viscosity 
(mPas) 
Refere
nce 
Standard 
breakfast 
(62% fat*) 
 
516± 6a 474±7.7a 1.09± 0.03a 
 
 
6.51± 0.01a,  
6.61± 0.03b 
 
 
    29.3± 0.9a, 
    30.1± 1.8b 
 
 
 
      771± 10 
  
  
   
     
          
     52± 1a,  
     44± 1b
 
 
 
  
 
   [43]
  
 
Standard 
breakfast 
(37% fat*) 
 
540± 5.5a 513± 7.3a 1.05± 0.03a 
 
5.28± 0.03a,  
5.12± 0.04b 
 
49.6± 1.7a,  
47.2± 1.5b 
713± 10 
     49± 1a,  
     45± 1b 
 [43] 
Milk 
(48.1% fat*) 
  1.03± 0.005a 
 
6.72± 0.02a, 
6.63± 0.01b 
14.4± 0.2a,  
13.9± 0.2b 
285± 2.7 
54.2± 0.4a,  
49.8± 0.6b 
 
 
1.9± 0.04a,  
[43] 
62 
 
 1.5± 0.04b
 
  
Partially 
digested milk 
(i. 3.5% fat 
milk, ii. milk 
+ HCl + 
pepsin, iii. 
Milk + HCl 
+ pepsin + 
lipase) 
   
i. 6.5,  
ii. 4.7-2.6 (in 
6 h),  
iii. 5.1-4 (in 
6h) 
i. 13-19 
ii. 19-38 
iii. 47-69 
      i. 260, 
     ii. 338-462, 
 iii. 475-540 
  [44] 
Ensure® 
(30.1% fat) 
  1.04± 0.016a 
 
6.68± 0.01a, 
6.58± 0.1b 
 
15.4± 0.1a, 16.4b 375± 3.5 
50.5± 0.2a,  
47.8± 0.1b 
6.3± 0.09a,  
4.4± 0.07b 
[43] 
Ensure 
 Plus® 
(29.1% fat) 
  1.08± 0.003a 
 
6.62± 0.03a, 
6.45± 0.02b 
 
20± 0.7a,  
21± 0.3b 
      730± 10   
53.2± 0.2a,  
48.4± 0.1b 
19.1± 0.1a,  
12.3± 0.1b 
[43] 
Early 
FeSSGF 
(milk based) 
   6.4 21.33 559   [37] 
63 
 
Middle 
FeSSGF 
(milk based) 
   5 25 400   [37] 
Late 
FeSSGF 
(milk based) 
   3 25 300   [37] 
Early 
FeSSGF 
(Lipofundin® 
 based) 
   6.4 21 559   [66] 
Middle 
FeSSGF 
(Lipofundin® 
 based) 
   5 25 400   [66] 
Late 
FeSSGF 
(Lipofundin® 
 based) 
   3 25 300   [66] 
Nutrison®    5.4  420   [5] 
FSGES    5     [125] 
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 1275 
  1276 
Intralipid® 
 30% 
     320  2.7± 0.06 [126] 
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Table 5. Composition of nutrient drinks/parenteral emulsions used as fed state gastric media 1277 
in vitro. 1278 
Nutrient drink Composition (per Litre)† 
Scandishake® mix 598 kcal, 30.4 g fat, 11.7 g protein, 69.5 g carbohydrate†† 
Ensure® 930 kcal, 25 g fat, 38 g protein, 135 g carbohydrate 
Ensure Plus® 1500 kcal, 46 g fat, 55 g protein, 210 g carbohydrate 
Nutrison® 1000 kcal, 39 g fat, 40 g protein, 123 g carbohydrate 
Intralipid® 30 3000 kcal, 300 g fat 
 1279 
† according to the manufacturer [63] (Ensure® and Ensure Plus® vanilla flavour) 1280 
†† 85 g powder in 240 mL whole milk. 1281 
  1282 
66 
 
Figure captions 1283 
Figure 1: mean pH values from aspirates of patients after administration of 500 mL Ensure 1284 
Plus® containing 10 mg/mL PEG 4000. (data extracted from [13]) 1285 
Figure 2. Schematic representation demonstrating the lipid digestion, formation of micelles 1286 
and drug absorption in the small intestine after administration of a meal; processes taking place 1287 
in the stomach in the highlighted rectangle. (modified from [22]) 1288 
Figure 3. Pharmacokinetic parameters after administration of two 100 mg itraconazole 1289 
capsules under fasted and fed (standard breakfast) state conditions. * denotes statistically 1290 
significant difference (p< 0.001, multivariate ANOVA). (data extracted from [68]) 1291 
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